Table 1.

Animal cohorts.

	Age at start	Route and dose	Duration	Sex	Rapamycin blood levels	Measures
Cohort 1	2–2.5 months	Enteric (chow) 14 ppm	10, 20 or 30 weeks	Male and female	1.62 ng/ml (F) 0.78 ng/ml (M)	Plaque area (IHC) Ventricle mass
Cohort 2	7 months	Intraperitoneal (10 mg/kg)	16 weeks	Male	Not measured (liver rapamycin levels of 14.1 pg/mg equivalent to 3–4 ng/ml in blood)	CBF and BVD (MRI)
Cohort 3	5 months	Enteric (chow) 14 ppm	15 weeks crossover	Male and female	Not measured	Plaque area (IHC)
Cohort 4	7 months	Enteric (chow) 14 ppm	16 weeks	Male	3–4 ng/ml	Memory (NOR, MWM)

mTOR: mechanistic target of rapamycin; AD: Alzheimer’s disease; LDL: low density lipoprotein; CBF: cerebral blood flow; BVD: brain vascular density; LDLR: low-density lipoprotein receptor; NO: nitric oxide; HFD: high fat diet; WT: wild type; MWM: Morris water maze; SN: spatial novelty; SAA: serum amyloid A; ApoE: apolipoprotein E; IL-6: interleukin 6.